BiovaxID™: A personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma

Expert Opinion on Biological Therapy

Volumn 7, Issue 1, 2007, Pages 113-122

  Lee, Seung Tae ^a   Jiang, Yun Fang ^a   Park, Keon Uk ^a   Woo, Alison F ^a   Neelapu, Sattva S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BiovaxID ; Clinical trials; Idiotype; Immunotherapy; Lymphoma; Rituximab; Vaccine

Indexed keywords

BIOVAXID; CANCER VACCINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDIOTYPIC ANTIBODY; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; IMMUNOGLOBULIN IDIOTYPE; NEW DRUG;

B LYMPHOCYTE; BONE PAIN; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER REGRESSION; CANCER SURVIVAL; CELLULAR IMMUNITY; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; FEVER; FLU LIKE SYNDROME; FOLLICULAR LYMPHOMA; HUMAN; HUMORAL IMMUNITY; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PRURITUS; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; ANIMAL; CELL CLONE; IMMUNOLOGY;

ANIMALS; CANCER VACCINES; CLONE CELLS; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNOGLOBULIN IDIOTYPES; LYMPHOMA, NON-HODGKIN;

EID: 33846144386     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.1.113     Document Type: Review

References (61)

1. JEMAL A, SIEGEL R, WARD E et al.: Cancer Statistics, 2006. CA Cancer J. Clin. (2006) 56:106-130.
2. GANDHI MK, MARCUS RE: Follicular lymphoma: time for a re-think? Blood Rev. (2005) 19(3):165-178.
3. HIDDEMANN W, KNEBA M, DREYLING M et al.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood (2005) 106(12):3725-3732.
4. FISHER RI, LE BLANC M, PRESS OW, MALONEY DG, UNGER JM, MiLLER TP: New treatment options have changed the survival of patients with follicular lymphoma. J. Clin. Oncol. (2005) 23(33):8447-8452.
5. CZUCZMAN MS, GRILLO-LOPEZ AJ, WHITE CA et al.: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antobody and CHOP chemotherapy. J. Clin. Oncol. (1999) 17:268-276.
6. CZUCMAN MS, WEAVER R, ALKUZWENY B, BERLFEIN J, GRILLO-LOPEZ AJ: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy:9-year follow-up. J. Clin. Oncol. (2004) 22(23):4711-4716
7. [Erratum in: J. Clin. Oncol. (2005) 23(1):248].
8. HORNING SJ, ROSENBERG SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N. Engl. J. Med. (1984) 311(23):1471-1475.
9. COLOMBAT P, SALLES G, BROUSSE N et al.: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood (2001) 97(1):101-106.
10. WITZIG TE, VUKOV AM, HABERMANN TM et al.: Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a Phase II trial in the North Central Cancer Treatment Group. J. Clin. Oncol. (2005) 23(6):1103-1108.
11. DAVE SS, WRIGHT G, TAN B et al.: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. (2004) 351(21):2159-2169.
12. SIRISINHA S, EISEN HN: Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc. Natl. Acad. Sci. USA (1971) 68:3130-3135.
13. LYNCH RG, GRAFF RJ, SIRISINHA S et al.: Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl. Acad. Sci. USA (1972) 69:1540-1544.
14. STEVENSON GT, STEVENSON FK: Antibody to a molecularly-defined antigen confined to a tumour cell surface. Nature (1975) 254:714-716.
15. FREEDMAN PM, AUTRY JR, TOKUDA S et al.: Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein. J. Natl. Cancer Inst. (1976) 56:735-740.
16. STEVENSON GT, ELLIOTT EV, STEVENSON FK: Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target. Fed. Proc. (1977) 36:2268-2271.
17. KAMINSKI MS, KITAMURA K, MALONEY DG et al.: Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J. Immunol. (1987) 138:1289-1296.
18. KWAK LW, CAMPBELL MJ, ZELENETZ AD et al.: Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin. Blood (1990) 76:2411-2417.
19. KWAK LW, YOUNG HA, PENNINGTON RW et al.: Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA (1996) 93:10972-10977.
20. EAGER R, NEMUNAITIS J: GM-CSF gene-transduced tumor vaccines. Mol. Ther. (2005) 12(1):18-27.
21. KWAK LW, CAMPBELL MJ, CZERWINSKI DK et al.: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. (1992) 327:1209-1215.
22. HSU FJ, CASPAR CB, CZERWINSKI D et al.: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood (1997) 89:3129-3135. References [20] and [21] describe the first human clinical trial of ID vaccination for follicular lymphoma.
23. BENDANDI M, GOCKE CD, KOBRIN CB et al.: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. (1999) 5(10):1171-1177. Demonstrated the induction of molecular remission with ID-KLH plus GM-CSF vaccination for follicular lymphoma.
24. BASKAR S, KOBRIN CB, KWAK LW: Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. J. Clin. Invest. (2004) 113(10):1498-1510.
25. BERTINETTI C, ZIRLIK K, HEINING-MIKESCH K et al.: Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Cancer Res. (2006) 66(8):4496-502. References [23] and [24] identified T-cell epitopes in the hypervariable complementarity-determining regions of the immunoglobulin molecule.
26. SANTOS C, STERN L, KATZ L, WATSON T, BARRY G: BiovaxID™ vaccine therapy of follicular lymphoma in first remission: long-term follow-up of a Phase II trial and status of a controlled, randomized Phase III trial. Blood (2005) 106:2441.
27. LONGO DL, DUFFEY PL, GRIBBEN JG et al.: Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a Phase II study. Cancer J. (2000) 6(3):146-150.
28. MALONEY DG, LILES TM, CZERWINSKI DK et al.: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood (1994) 84:2457-2466.
29. MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. (1998) 16:2825-2833.
30. NEELAPU SS, KWAK LW, KOBRIN CB et al.: Vaccine induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat. Med. (2005) 11(9):986-991. Demonstrated that tumor-specific T-cell responses can be induced in the absence of B cells in humans.
31. NEELAPU SS, GAUSE BL, NIKCEVICH DA et al.: Phase III randomized trial of patient-specific vaccination for previously untreated follicular lymphoma patients in first complete remission: protocol summary and interim report. Clin. Lymphoma (2005) 6(1):61-64.
32. VOSE JM: Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach. Hematol. Oncol. (2006) 24(2):47-55.
33. HURVITZ SA, TIMMERMAN JM: Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opin. Biol. Ther. (2005) 5(6):841-852.
34. TIMMERMAN JM, CASPAR CB, LAMBERT SL, SYRENGELAS AD, LEVY R: Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood (2001) 97(5):1370-1377.
35. TIMMERMAN JM, LEVY R: Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J. Immunol. (2000) 164(9):4797-4803.
36. LEVITSKY HI, MONTGOMERY J, AHMADZADEH M et al.: Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J. Immunol. (1996) 156(10):3858-3865.
37. KWAK LW, PENNINGTON R, BONI L, OCHOA AC, ROBB RJ, POPESCU MC: Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. J. Immunol. (1998) 160(8):3637-3644.
38. WENG WK, CZERWINSKI D, TIMMERMAN J, HSU FJ, LEVY R: Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol. (2004) 22(23):4717-4724
39. [Erratum in: J. Clin. Oncol. (2005) 23(1):248].
40. KEILHOLZ U, WEBER J, FINKE J et al.: Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunother. (2002) 25:97-138.
41. MALYGUINE A, STROBL SL, SHAFER-WEAVER KA et al.: A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. J. Transl. Med. (2004) 2(1):9.
42. HSU FJ, BENIKE C, FAGNONI F et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. (1996) 2:52-58.
43. TIMMERMAN JM, CZERWINSKI DK, DAVIS TA et al.: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood (2002) 99:1517-1526.
44. NEELAPU SS, BASKAR S, GAUSE BL et al.: Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin. Cancer Res. (2004) 10(24):8309-8317.
45. NELSON EL, LI X, HSU FJ et al.: Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood (1996) 88(2):580-589.
46. PASHINE A, VALIANTE NM, ULMER JB: Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. (2005) 11(4 Suppl.):S63-S68.
47. SHACKLETON M, DAVIS ID, HOPKINS W et al.: The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. (2004) 4:9.
48. SPEISER DE, LIENARD D, RUFER N et al.: Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. (2005) 115(3):739-746.
49. WALKER LS, ABBAS AK: The enemy within: keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol. (2002) 2(1):11-19.
50. CHEN L: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. (2004) 4(5):336-347.
51. ZOU W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer (2005) 5(4):263-274. An excellent review of immunosuppressive pathways within the tumor microenvironment.
52. SAKAGUCHI S: Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. (2005) 6(4):345-352.
53. CARTER LL, CARRENO BM: Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation. Immunol. Res. (2003) 28(1):49-59.
54. SUTMULLER RP, VAN DUIVENVOORDE LM, VAN ELSAS A et al.: Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. (2001) 194(6):823-832.
55. IWAI Y, ISHIDA M, TANAKA Y, OKAZAKI T, HONJO T, MINATO N: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA (2002) 99(19):12293-12297.
56. IWAI Y, TERAWAKI S, HONJO T: PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. (2005) 17(2):133-144.
57. CURIEL TJ, WEI S, DONG H et al.: Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. (2003) 9(5):562-567.
58. DANNULL J, SU Z, RIZZIERI D et al.: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. (2005) 115(12):3623-3633. Demonstrated that the depletion of Tregs using Ontak can enhance vaccine-induced T-cell responses.
59. BARNETT B, KRYCZEK I, CHENG P, ZOU W, CURIEL TJ: Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am. J. Reprod. Immunol. (2005) 54(6):369-377.
60. PHAN GQ, YANG JC, SHERRY RM et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA (2003) 100(14):8372-8377.
61. HODI FS, MIHM MC, SOIFFER RJ et al.: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA (2003) 100(8):4712-4717. References [57] and [58] demonstrated that administration of anti-CTLA-4 antibody could induce tumor regression in cancer patients.